pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis
Ipsen
Ipsen is a pharma organization headquartered in Paris, FR. Primary therapeutic focus areas include Metastatic Pancreatic Adenocarcinoma, Primary Biliary Cholangitis, Episodic Migraine, Alagille Syndrome, Not applicable.
Company details
- Status
- Public
- HQ
- 70, Rue Balard, Paris, Île-de-France 75015, FR
- Employees
- 6,584
- Programs
- 27
- Drugs
- 36
- Patents
- 0
F-FR-60000-023
Phase 2 · small molecule · Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
F-FR-60000-023 for Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors is a Phase 2 program (small_molecule) at Ipsen with 1 ClinicalTrials.gov record(s).
Internal code F-FR-60000-023
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ipsen
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
- Status
- active
- Trials
- 1